Quimioterapia neoadjuvante torna ressecável carcinoma de cabeça de pâncreas

Quimioterapia neoadjuvante torna ressecável carcinoma de cabeça de pâncreas

We present a case of non-resectable head pancreatic cancer by mesenteric venous invasion in which treatment with Gemcitabine (Gemzar) 1.000 mg/m 2 weekly for 3 weeks, followed by a 1-week rest, normalized CA 19.9 and promoted tumor resecability in a second operation (ultrasound, helicoidal tomograph...

Full description

Bibliographic Details
Main Authors:	Marco Antônio Cezário de Melo, Christiane Violet
Format:	Article
Language:	English
Published:	Colégio Brasileiro de Cirurgiões
Series:	Revista do Colégio Brasileiro de Cirurgiões
Subjects:	Pancreatic neoplasms Pancreaticoduodenectomy Drug therapy Neoadjuvant therapy, Gemcitabine
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912007000400014&lng=en&tlng=en

Similar Items

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)

Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
by: Daniel Herchenhorn, et al.
Published: (2007-10-01)

Perception versus reality: A National Cohort Analysis of the surgery‐first approach for resectable pancreatic cancer
by: John R. Bergquist, et al.
Published: (2021-09-01)

Solid pseudopapillary tumors of the pancreas: 27 cases from a single institution
by: ZHOU Haiyang
Published: (2013-01-01)

Concurrent presentation of an intraductal tubulopapillary neoplasm and intraductal papillary mucinous neoplasm in the branch duct of the pancreas, with a superior mesenteric artery aneurysm: a case report
by: Kenta Inomata, et al.
Published: (2018-04-01)

Carcinoma ressecável do esôfago: controle local com quimioterapia e radioterapia neoadjuvantes
Published: (2002-01-01)

Fatores prognósticos pré-operatórios em pacientes com adenocarcinoma ductal da cabeça do pâncreas
by: João Bernardo Sancio, et al.

Comparison of Quality of Life before and after pancreaticoduodenectomy: a prospective study
by: Maria Arvaniti, et al.
Published: (2018-07-01)

Emphasis on neoadjuvant therapy for “resectable” pancreatic cancer
by: LIU Chang
Published: (2015-05-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Avaliação da expressão da proteína EZH2 na resposta do carcinoma de mama localmente avançado à quimioterapia neoadjuvante
by: Lucienne Pereira Del Grossi Neusquen
Published: (2012)

Avaliação da expressão da proteína EZH2 na resposta do carcinoma de mama localmente avançado à quimioterapia neoadjuvante
by: Neusquen, Lucienne Pereira Del Grossi
Published: (2012)

Contemporary Management of Localized Resectable Pancreatic Cancer
by: Anuhya Kommalapati, et al.
Published: (2018-01-01)

Avaliação imunoistoquímica dos receptores de estrogênio e progesterona no câncer de mama, pré e pós-quimioterapia neoadjuvante
by: Jan Pawel Andrade Pachnicki, et al.

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)
by: Suizhi Gao, et al.
Published: (2019-03-01)

Clinical application of duodenum-preserving pancreatic head resection
by: ZHOU Songqiang
Published: (2018-01-01)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
by: Daisaku Yamada, et al.
Published: (2021-08-01)

Current status and perspectives of neoadjuvant therapy for pancreatic cancer
by: LIANG Tingbo
Published: (2019-05-01)

Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer
by: Yi-Nan Shen, et al.
Published: (2018-12-01)

Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study
by: Nicolò Pecorelli, et al.
Published: (2019-11-01)

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
by: Fabiana Napolitano, et al.
Published: (2019-07-01)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
by: Gong DJ, et al.
Published: (2013-07-01)

Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis
by: Joseph A. Miccio, et al.
Published: (2021-03-01)

Delayed Hemorrhage of the Hepatic Artery Caused by Biliary Stenting after Concurrent Chemoradiotherapy
by: Joon Ho Cho, et al.
Published: (2020-09-01)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
by: Ren X, et al.
Published: (2019-01-01)

Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
by: Jong-Mu Sun
Published: (2020-08-01)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
by: Aurélien Lambert, et al.
Published: (2021-09-01)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01)

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
by: Fuyuhiko Motoi, et al.
Published: (2020-03-01)

Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer—A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
by: Baba, T., et al.
Published: (2022)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
by: Lv W, et al.
Published: (2016-05-01)

Pesquisa do Linfonodo Sentinela em Pacientes portadoras de CÃncer de Mama localmente avanÃado e submetidas Ã quimioterapia neoadjuvante
by: Paulo Henrique Walter de Aguiar
Published: (2007)

Perfil transcricional e resposta à quimioterapia neoadjuvante em câncer de mama Transcriptional profile and response to neoadjuvante chemotherapy in breast cancer
by: Maria Aparecida Azevedo Koike Folgueira, et al.
Published: (2011-06-01)

Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy
by: Aziz Rezapour, et al.
Published: (2018-01-01)

Primary small cell carcinoma of the pancreas: rare type of pancreatic cancer and review of the literatures
by: Wang Dansong, et al.
Published: (2012-02-01)

Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective
by: Yoshihiro Kurata, et al.
Published: (2021-03-01)

Análisis de la mortalidad posoperatoria temprana en una cohorte de 132 pacientes sometidos a cirugía de Whipple en Medellín
by: Jaime Chávez, et al.

Modelling combined chemotherapy and particle therapy for locally advanced pancreatic cancer
by: Marco eDurante, et al.
Published: (2015-07-01)

Fístula pancreática após duodenopancreatectomia: correlação dos aspectos intra-operatórios e histologicos do pâncreas
by: Fernando Leal Pereira, et al.

Sentinel lymph node biopsy in patients with locally advanced breast cancer after neoadjuvant chemotherapy Biopsia do linfonodo sentinela em câncer na mama localmente avançado pós-quimioterapia neoadjuvante
by: Paulo Henrique Walter Aguiar, et al.
Published: (2012-12-01)